Author

A. J. Valvezan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Research Focus:metabolism & bioenergetics· 1 Organism:mouse· 1

Frequent Co-Authors

B. D. Manning· 2 shared B. E. Housden· 1 shared C. Kelley· 1 shared E. P. Henske· 1 shared J. M. Asara· 1 shared M. C. McNamara· 1 shared M. E. Torrence· 1 shared N. Perrimon· 1 shared

Activity by Year

2017-2019 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. D. Manning

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

IMPDH inhibitors for anti-tumor therapy in tuberous sclerosis complex

A. J. Valvezan, S. K. Miller, M. C. McNamara, M. E. Torrence, J. M. Asara, E. P. Henske, B. D. Manning

This paper evaluates IMPDH inhibitors for anti-tumor therapy in TSC, finding mizoribine more effective than mycophenolic acid in targeting mTORC1-driven tumors.

bioRxiv · Nov 11, 2019Cancer Biology

Variable dose analysis: A novel RNAi-based method for detection of synthetic lethal interactions

B. E. Housden, Z. Li, C. Kelley, Y. Wang, Y. Hu, A. J. Valvezan, B. D. Manning, N. Perrimon

This paper introduces a novel RNAi-based method called variable dose analysis (VDA) to detect synthetic lethal interactions, identifying four FDA-approved drugs for TSC-related tumors.

bioRxiv · Aug 16, 2017Cancer Biology